CLL Trends over 28 years, and it’s all good ne... - CLL Support
CLL Trends over 28 years, and it’s all good news, even before we count the new drugs now just becoming available.
You need to be a member of this community to see this post.
4 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Richter Transformation Survival in CLL Appears Better Among Treatment-Naive
A new nationwide study showed that the 5-year cumulative incidence of Richter transformation (RT)...
Potential Early Drivers of Disease in Treatment-Naive CLL Identified
This study reinforces others regarding mutations that predict a short time to first treatment....
EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor
https://cllsociety.org/2022/08/eha-2022-outcomes-following-treatment-with-a-covalent-btk-and-bcl2-in
Acalabrutinib Plus Obinutuzumab Prolongs Progression Free Survival Compared to Other Targeted Agents in Chronic Lymphocytic Leukaemia (CLL)
First-line acalabrutinib plus obinutuzumab prolongs progression-free survival (PFS) compared to...
Following LeoPa's “On CLL, diet and possible connections.”
I am also curious about the preferred energy source of CLL cells.
Particularly the cholesterol...
Related Posts
Clinical trial results & reviews of new treatments for CLL written in easy to understand terms - Health Canada approves Ibrutinib plus Rituximab for First Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
- Dr. John Allan - Chronic Lymphocytic Leukemia (CLL) Patients @Undetectable Measurable Residual Disease (MRD) after Ibrutinib Plus Venetoclax
- "Accelerated" chronic lymphocytic leukemia/small lymphocytic lymphoma: unraveling CLL/SLL biological gray zone in the era of novel therapies
RICHTER'S TRANSFORMATION IN PATIENTS WITH CLL: ANALYSIS OF BIOLOGICAL AND CLINICAL RISK FACTORS AND OUTCOMES
